What's Happening?
Scribe Therapeutics, a biotechnology company based in Alameda, California, has received regulatory clearance from the Australian Therapeutic Goods Administration to begin a first-in-human clinical study of STX-1150. This investigational therapy aims to reduce
low-density lipoprotein cholesterol (LDL-C) by epigenetically silencing the PCSK9 gene, a key regulator of cholesterol. The therapy uses Scribe's proprietary ELXR technology to achieve long-lasting gene silencing in the liver without altering DNA permanently. The Phase 1 study will assess the safety, tolerability, and efficacy of STX-1150 in adults with elevated LDL-C, with trial sites in Australia and New Zealand.
Why It's Important?
This development marks a significant milestone in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD), which are major health concerns globally. By potentially offering a long-lasting solution to LDL-C reduction, STX-1150 could transform the standard of care for patients with chronic cardiometabolic diseases. The therapy's ability to provide sustained cholesterol lowering after a single dose could address adherence challenges associated with current treatments, which require ongoing administration. This advancement could benefit patients by reducing the burden of lifelong medication and improving cardiovascular outcomes.
What's Next?
The clinical trial will involve up to 64 participants and is designed as an open-label, single ascending dose trial followed by a dose expansion phase. Participants will be monitored for one year post-treatment. The study's outcomes could pave the way for broader clinical applications of Scribe's CRISPR-based technologies. If successful, STX-1150 could lead to new therapeutic options for managing cholesterol and reducing cardiovascular risk, potentially influencing treatment guidelines and healthcare practices worldwide.
